TANs could produce proinflammatory factors such as monocyte chemoattractant protein-1, interleukin-8, macrophage inflammatory protein-1 alpha, interleukin-6 (IL-6), and anti-inflammatory interleukin 1 receptor antagonist (IL-1RA), thereby bolstering anti-tumor immunity in early-stage lung cancer [17]. This evidence concerns the gene IL6 and lung carcinoma.